Ewopharma News - LARVOL Sigma

12 3 4 5 6 7 »

|||||||||| namodenoson (CF102) - Can / Fite, piclidenoson (CF101) - Can / Fite
Review, Journal: Adenosine A3 Receptor: From Molecular Signaling to Therapeutic Strategies for Heart Diseases. (Pubmed Central) - Jun 19, 2024
Several A3AR-specific agonists, such as piclidenoson and namodenoson, exert cardioprotective impacts during ischemia in the diverse animal models of heart disease. Thus, modulating A3ARs serves as a potential therapeutic approach, fueling considerable interest in developing compounds that target A3ARs as potential treatments for heart diseases.

|||||||||| namodenoson (CF102) - Can / Fite
Journal: Gene regulation in activated microglia by adenosine A receptor agonists: a transcriptomics study. (Pubmed Central) - Jun 18, 2024
Analysis of known and predicted protein-protein interactions showed that Smad3 and Sp1 are transcription factors whose genes are regulated by AR activation. Under the conditions of cell activation and agonist treatment regimen, 2-Cl-IB-MECA did not lead to any tendency to favor the expression of genes related to neuroprotective microglia (M2).

|||||||||| Erelzi (etanercept-szzs) / Sandoz
Journal: Charting the Etanercept Journey: Tracing Cost Dynamics in Poland's Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly. (Pubmed Central) - Jun 11, 2024
This nation-level scenario of market re-monopolization by a biosimilar drug confirms net loss and excess costs for the healthcare payer, as can be expected from economic theory. The upwards drug repricing and restriction of treatment availability occurs much more rapidly than the decrement in a period of market competition.

|||||||||| Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma, Bionovis
TRANSITIONING BACK AND FORTH BETWEEN BIO-ORIGINATOR ETANERCEPT AND BIOSIMILAR SB4 IN CLINICAL PRACTICE: IMPACT ON DRUG SURVIVAL AND DISEASE ACTIVITY () - May 29, 2024 - Abstract #EULAR2024EULAR_4051;
No significant differences were found between patients who previously had or had not used the bio-originator. Therefore, transitioning back and forth between biosimilar and bio-originator can be used in clinical practice to achieve cost-effective care.

|||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
A real-world study of anlotinib in combination with PD-L1 inhibitors plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6752;
The addition of anlotinib to first-line immunotherapy in combination with chemotherapy results in extended PFS and OS in patients with ES-SCLC without additional AEs. The preliminary results warrant further investigation of this treatment modality in ES-SCLC.

|||||||||| Cejemly (sugemalimab) / CStone Pharma
Sugemalimab in locally advanced and advanced Chinese NSCLC: A real-world retrospective study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5889;
Our study demonstrated Sugemalimab-based therapy provide clinical benefits to LA-NSCLC and mNSCLC with good safety in real-world setting. The combination treatment of Sugemalimab with radiotherapy illustrates low pulmonary toxicity and superior tolerability.

|||||||||| Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma, Bionovis
Preclinical, Journal: Effect of using scan body accessories and inter-implant distances on the accuracy of complete arch implant digital impressions: An in vitro study. (Pubmed Central) - Apr 10, 2024

||||||||||  Remicade (infliximab) / J&J, Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
Trial completion date, Trial primary completion date, Adverse events, Combination therapy, Metastases:  PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma (clinicaltrials.gov) -  Mar 21, 2024
P2, N=36, Recruiting,  Sponsor: Massachusetts General Hospital
The combination treatment of Sugemalimab with radiotherapy illustrates low pulmonary toxicity and superior tolerability. Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2023 --> Jun 2025

||||||||||  Remicade (infliximab) / J&J, Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
Trial completion date, Trial primary completion date, Checkpoint inhibition:  Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis (clinicaltrials.gov) -  Mar 15, 2024
P2, N=42, Recruiting,  Sponsor: Massachusetts General Hospital
Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2023 --> Jun 2025 Trial completion date: Jun 2023 --> Jun 2030 | Trial primary completion date: Jun 2023 --> Jun 2030

|||||||||| Erelzi (etanercept-szzs) / Sandoz, Hyrimoz (adalimumab-adaz) / Sandoz, Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma, Bionovis
Clinical data, Observational data, Retrospective data, Journal: Forty-Eight-Month Monitoring of Disease Activity in Patients with Long-Standing Rheumatoid Arthritis Treated with TNF-? Inhibitors: Time for Clinical Outcome Prediction and Biosimilar vs Biologic Originator Performance. (Pubmed Central) - Mar 5, 2024
We conclude that biosimilars of adalimumab and etanercept have equivalent effectiveness over a long period of time compared to their originator drugs, and also that the levels of disease activity after 6 months of tumor necrosis factor-? inhibitors (originator drugs and biosimilars) might predict the response to therapy at 4 years in patients with long-standing rheumatoid arthritis.

|||||||||| hyoscine butylbromide oral / Generic mfg.
Preclinical, Journal: Vanillin derivatives as antiamnesic agents in scopolamine-induced memory impairment in mice. (Pubmed Central) - Feb 29, 2024
inhibitors (originator drugs and biosimilars) might predict the response to therapy at 4 years in patients with long-standing rheumatoid arthritis. The compounds; SB-1, SB-3, SB-4 and SB-6 more potently inhibited AChE with IC50 values of 0.078, 0.157, 0.108, and 0.014

|||||||||| Phase classification: CAMEO: Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease (clinicaltrials.gov) - Feb 15, 2024
P4, N=900, Recruiting, Sponsor: Connecticut Children's Medical Center
The compounds; SB-1, SB-3, SB-4 and SB-6 more potently inhibited AChE with IC50 values of 0.078, 0.157, 0.108, and 0.014 Phase classification: P --> P4

|||||||||| Erelzi (etanercept-szzs) / Sandoz
Similar Treatment Adherence Between Individuals with Rheumatic Diseases Treated with Etanercept Originator and Biosimilar: a Population-Based Study () - Feb 8, 2024 - Abstract #CRAAHPA2024CRA_AHPA_153;
Low adherence is common among these patients but better in older individuals. Limitations of our analyses include our assumption that every individual was under same regimens and that reasons for nonadherence/treatment gaps are not available in claims data.

|||||||||| Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
The Biosimilar Switch: IBD nurse's experience in Our Lady of Lourdes Hospital (Poster exhibition) - Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_1375;
Results 86 patients were switched from the originator to the biosimilar Flixabi...Conclusion Of the 86 patients who were switched 22 responded to the questionnaire. 21 patients were happy with their overall experience with how the switch was conducted.

|||||||||| Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma
Journal: Copper(II)-photocatalyzed Hydrocarboxylation of Schiff bases with CO: antimicrobial evaluation and in silico studies of Schiff bases and unnatural ?-amino acids. (Pubmed Central) - Jan 9, 2024
In silico studies revealed strong binding strengths with E. faecalis DHFR (4M7U) for docked Schiff bases (SB) and unnatural ?-amino acids (UAAs). In vitro studies further demonstrated significant antimicrobial and antifungal activity for SB2, SB3, and SB4, while none of the synthesized UAAs exhibited such properties, primarily due to the electronic and binding properties of these molecules.Communicated by Ramaswamy H. Sarma.

|||||||||| Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
Reimbursement, US reimbursement, Journal, Medicare: Filgrastim and infliximab biosimilar uptake in Medicare Advantage compared with Traditional Medicare, 2016-2019. (Pubmed Central) - Jan 2, 2024
Our findings suggest that filgrastim and infliximab biosimilar uptake is greater in MA compared with Traditional Medicare, which is driven in part by particularly high uptake of biosimilars in MA Kaiser HMO plans. This highlights the need for future work to examine specific strategies and levers employed by MA Kaiser HMO plans and other insurers to increase biosimilar uptake, which can lead to cost savings for physician-administered drugs.

|||||||||| Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
Journal: Outcomes of the use of infliximab biosimilars in rheumatology and gastroenterology clinics. (Pubmed Central) - Jan 2, 2024
We conclude that the effort to convert clinically stable patients to a biosimilar product resulted in a significant increase in biosimilar use within the health system. This is thought to have resulted in significant financial advantages both to our institution as well as patients, without sacrificing overall clinical control.

|||||||||| Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo, Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma
Journal: Anti-tumor necrosis factor ?: originators versus biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies. (Pubmed Central) - Dec 24, 2023
Real-life data demonstrated a similar safety profile between biosimilars and originators, but a reduced biosimilar retention rate at 24 months. Biosimilars could be considered a valid, safe, and less expensive alternative to originators, allowing access to treatments for a wider patient population.

|||||||||| Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
INFLIXIMAB AND ITS BIOSIMILARS FOR INFLAMMATORY BOWEL DISEASE: ANALYSIS OF MEDICARE PART D CLAIMS AND COSTS (Bellagio Ballroom - Bellagio Las Vegas) - Dec 24, 2023 - Abstract #CCCongress2024CCCongress_285;
At the national level, biosimilars exhibited increased utilization. In contrast, both the utilization and cost of infliximab continued to rise; however, the rate of increase decelerated (Table 1).

|||||||||| Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma
Preclinical, Journal: Influence of scanbody design and intraoral scanner on the trueness of complete arch implant digital impressions: An in vitro study. (Pubmed Central) - Dec 23, 2023
In contrast, both the utilization and cost of infliximab continued to rise; however, the rate of increase decelerated (Table 1). Seven scanbodies (SB1, SB2, SB3, SB4, SB5, SB6, and SB7) and four intraoral scanners (Primescan

|||||||||| Enrollment status, Trial completion date, Trial primary completion date: FREE: De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease (clinicaltrials.gov) - Nov 30, 2023
P4, N=148, Enrolling by invitation, Sponsor: University Medical Center Groningen
Seven scanbodies (SB1, SB2, SB3, SB4, SB5, SB6, and SB7) and four intraoral scanners (Primescan Recruiting --> Enrolling by invitation | Trial completion date: Jun 2023 --> Mar 2025 | Trial primary completion date: Jun 2023 --> Mar 2025

|||||||||| Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma
Journal: Comparative Analysis of Anticonvulsant Activity of Trans and Cis 5,5'-Diphenylhydantoin Schiff Bases. (Pubmed Central) - Nov 29, 2023
Our results suggest that trans-cis conversion of 5,5'-diphenylhydantoin Schiff bases has potential against seizure spread in the MES test and mitigated the KA-induced SE. The antioxidant potency of cisSB4-Ph might be associated with its efficacy in mitigating the SE.

||||||||||  Cejemly (sugemalimab) / CStone Pharma
Trial completion, Trial completion date, Combination therapy, Metastases:  GEMSTONE-303: A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma (clinicaltrials.gov) -  Nov 29, 2023
P3, N=479, Completed,  Sponsor: CStone Pharmaceuticals
The antioxidant potency of cisSB4-Ph might be associated with its efficacy in mitigating the SE. Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Sep 2023

|||||||||| Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma
Journal, HEOR: Comparative effectiveness of etanercept originator and biosimilar for treating rheumatoid arthritis: implications for cost-savings. (Pubmed Central) - Nov 28, 2023
Treatment persistence using either ETN originator or biosimilar was similar. The cost of all brands of ETN markedly reduced upon listing of the ETN biosimilar, resulting in significant savings for the Australian Government.

|||||||||| phenytoin / Generic mfg.
Journal: Additive Anticonvulsant Profile and Molecular Docking Analysis of 5,5'-Diphenylhydantoin Schiff Bases and Phenytoin. (Pubmed Central) - Nov 25, 2023
These data, combined with the worst interaction energies of our ligands with the mu receptor, suggest that the primary mechanism of their action involves the kappa and delta receptors, where the selectivity to the kappa receptor leads to higher biological effects. Our findings suggest that the four Schiff bases might be promising candidates with potential applications as a safe and effective adjuvant in epilepsy.

|||||||||| Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
Comparing Uptake of Biosimilar Infliximab Among Patients with Medicare, Medicaid and Private Insurance in U.S. Rheumatology Practices 2016-2022 (Room 33A-C; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_1787;
Medicare uptake lagged significantly. To reduce drug spending, efforts are needed to understand poor Medicare uptake of biosimilars such as manufacturer rebates for biologics, and lack of financial incentives to switch to biosimilars.

|||||||||| Hadlima (adalimumab-bwwd) / Organon, Biogen, Samsung, Mundipharma, Yuhan Corp, Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma
Review: Healthcare Professional (HCP) and Patient Usability Evaluation and Preferences of Two Auto-injector Devices for Self-Injection of Biosimilars, SB4 and SB5: A Literature Review. (Pubmed Central) - Aug 24, 2023
Therefore, they were preferred over the other reference product autoinjectors. Because user-friendly devices can improve treatment adherence, pharmaceutical companies should consider patient convenience when developing medical devices.

||||||||||  Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
Enrollment open, Trial initiation date:  REMODEL-CD: Precise Infliximab Exposure and Pharmacodynamic Control (clinicaltrials.gov) -  Jul 20, 2023
P2/3, N=180, Recruiting,  Sponsor: Children's Hospital Medical Center, Cincinnati
Because user-friendly devices can improve treatment adherence, pharmaceutical companies should consider patient convenience when developing medical devices. Not yet recruiting --> Recruiting | Initiation date: Apr 2023 --> Jul 2023

|||||||||| Journal: Expanded table: Some drugs for inflammatory bowel disease. (Pubmed Central) - Jul 11, 2023
Not yet recruiting --> Recruiting | Initiation date: Apr 2023 --> Jul 2023 No abstract available

|||||||||| Enrollment open: CAMEO: Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease (clinicaltrials.gov) - Jul 10, 2023
P=N/A, N=900, Recruiting, Sponsor: Connecticut Children's Medical Center
No abstract available Not yet recruiting --> Recruiting

|||||||||| Erelzi (etanercept-szzs) / Novartis, Humira (adalimumab) / Eisai, AbbVie, Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma
EIGHT-MONTH FOLLOW-UP OF THE NON-MEDICAL SWITCH FROM ETANERCEPT BIO-ORIGINATOR TO GP-2015 OR SB4 ETANERCEPT BIOSIMILARS IN PATIENTS WITH CHRONIC INFLAMMATORY ARTHROPATHIES: A MONOCENTRIC OBSERVATIONAL STUDY () - May 19, 2023 - Abstract #EULAR2023EULAR_3184;
Conclusion Our data indicate that the switch to GP-2015 or SB4 ETA biosimilars from ETA bio-originator does not bear clinical and laboratory differences in patients with chronic arthropathies. The worse outcome in PROs, which we also observed in the adalimumab bio-originator to biosimilar switch (3), does not reflect a worsening of disease activity indexes and could indicate a possible nocebo response.

|||||||||| Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
ADVANTAGE OF FIRST-LINE TDM-DRIVEN USE OF INFLIXIMAB FOR TREATING ACUTE INTESTINAL AND LIVER GVHD IN CHILDREN: A PROSPECTIVE, SINGLE-CENTER STUDY. (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1590;
The worse outcome in PROs, which we also observed in the adalimumab bio-originator to biosimilar switch (3), does not reflect a worsening of disease activity indexes and could indicate a possible nocebo response. All patients received infliximab biosimilars Inflectra

|||||||||| Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
Journal, HEOR, Real-world evidence, Real-world: Real-world evidence of the use of the infliximab biosimilar SB2: data from the PERFUSE study. (Pubmed Central) - May 1, 2023
P=N/A
All patients received infliximab biosimilars Inflectra SB2 was safe and effective in IFX-na

|||||||||| Trial completion date, Trial initiation date, Trial primary completion date: CAMEO: Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease (clinicaltrials.gov) - Apr 24, 2023
P=N/A, N=900, Not yet recruiting, Sponsor: Connecticut Children's Medical Center
SB2 was safe and effective in IFX-na Trial completion date: Apr 2029 --> Jul 2029 | Initiation date: Apr 2023 --> Jul 2023 | Trial primary completion date: Apr 2028 --> Jul 2028

|||||||||| Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma
An Evaluation of Patient Experience of the Belfast Health and Social Care Trust Rheumatology Etanercept Biosimilar Switch Programme. (Poster View) - Apr 2, 2023 - Abstract #EULAR2023EULAR_2460;
Background The Belfast Health and Social Care Trust Rheumatology department commenced a biosimilar switch programme in July 2019, switching patients from Etanercept (Enbrel) to biosimilar (Benepali)...Conclusion The Etanercept biosimilar switch programme was successful with high switch rates, high levels of patient confidence and satisfaction. Recommendations for future include improving the process of shared decision-making during consultation to ensure fully informed patient consent.

|||||||||| Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
Uptake of infliximab biosimilars among U.S. rheumatology practices through 2022 (Poster View) - Apr 2, 2023 - Abstract #EULAR2023EULAR_2021;
Figure 1. Proportion of patients in the RISE registry using infliximab bio-originator or biosimilars between 2016 and 2022.

|||||||||| New trial: CAMEO: Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease (clinicaltrials.gov) - Mar 23, 2023
P=N/A, N=900, Not yet recruiting, Sponsor: Connecticut Children's Medical Center

|||||||||| Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
Clinical, Observational data, Journal: PERFUSE: a French non-interventional study of patients with inflammatory bowel disease receiving infliximab biosimilar SB2: a 12-month analysis. (Pubmed Central) - Mar 21, 2023
Flixabi (SB2) is a biosimilar of the reference infliximab (IFX), Remicade...No immunogenicity or safety signals were detected. Patients with IBD can be initiated on SB2 or transitioned from IFX ref and/or IFX bs to SB2, with no loss of disease control or safety concerns, with >75% of naive and >90% of transitioned patients continuing on SB2 treatment at 12?months.

|||||||||| Eticovo (etanercept-ykro) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Review, Journal: Managing spot blotch disease in wheat: Conventional to molecular aspects. (Pubmed Central) - Mar 10, 2023
Despite, marker assisted breeding for SB resistance in wheat is scarce. Better understanding of wheat genome assemblies, functional genomics and cloning of resistance genes will further accelerate breeding for SB resistance in wheat.

|||||||||| Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
Observational data, P4 data, Journal: Safety and Effectiveness of SB2 (Infliximab Biosimilar) in Adult Patients with Immune-Mediated Inflammatory Diseases: A Post-Marketing Surveillance in Korea. (Pubmed Central) - Mar 9, 2023
Better understanding of wheat genome assemblies, functional genomics and cloning of resistance genes will further accelerate breeding for SB resistance in wheat. This PMS study of the IFX-biosimilar SB2 in Korea confirmed the safety and effectiveness of SB2 in major indications.

|||||||||| Humira (adalimumab) / Eisai, AbbVie, Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
Are Biosimilars Equivalent to Originator Molecules in the Real-World? Assessments of Efficacy, Toxicity, and Tolerability of Infliximabs in Infliximab-Na () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_1676;
569 study patients: 255 INFLIXIMAB (IFX), 111 INFLIXIMAB-ABDA (ABDA), AND 203 INFLIXIMAB-DYYB (DYYB)... In this study of infliximab-na

||||||||||  Cejemly (sugemalimab) / CStone Pharma
Trial primary completion date, Combination therapy, Metastases:  GEMSTONE-303: A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma (clinicaltrials.gov) -  Feb 16, 2023
P3, N=479, Active, not recruiting,  Sponsor: CStone Pharmaceuticals
In this study of infliximab-na Trial primary completion date: Aug 2022 --> May 2023

|||||||||| Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
ADVANTAGE OF FIRST-LINE TDM-DRIVEN USE OF INFLIXIMAB FOR TREATING ACUTE INTESTINAL AND LIVER GVHD IN CHILDREN: A PROSPECTIVE, SINGLE-CENTER STUDY (ePoster Area) - Feb 11, 2023 - Abstract #EBMT2023EBMT_1375;
P
Trial primary completion date: Aug 2022 --> May 2023 All patients received infliximab biosimilars Inflectra

|||||||||| Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
Journal: PERFUSE: Non-interventional cohort study of patients receiving infliximab biosimilar SB2; results in paediatric patients. (Pubmed Central) - Feb 3, 2023
Clinical remission rates improved in naïve patients and no loss of control was observed in switched patients after 1 year. Growth failure is not observed in IBD patients under SB2 treatment.

|||||||||| Eticovo (etanercept-ykro) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Journal: Effectiveness and Persistence in SB4 and Reference Etanercept-Treated Rheumatoid Arthritis Patients in Ordinary Clinical Practice in Norway. (Pubmed Central) - Feb 2, 2023
Growth failure is not observed in IBD patients under SB2 treatment. Outcomes for disease status/drug persistence at W52 were similar between patients with RA treated with etanercept or SB4.

|||||||||| Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
Well, some folks don’t take well to the switch to biosimilars. I immediately formed antibodies myself after being switched from Remicade to renflexis. Only three of us at my infusion facility had this happen, but that seems kind of high to me. (Twitter) - Feb 1, 2023

|||||||||| Eticovo (etanercept-ykro) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Preclinical, Journal: How the geometry of the scan body affects the accuracy of digital impressions in implant supported prosthesis. In vitro study. (Pubmed Central) - Jan 6, 2023
The scan bodies PRMG (SB3) and TALL (SB4) lead to smaller errors in distance, projected height and angulation than ELOS (SB1) and MG (SB2)...Any marginal discrepancy may lead to the failure of the rehabilitation or the implant due to the associated biomechanical problems. Key words:IOS, CAD/CAM, SCAN Bodies.

|||||||||| Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Journal: Risankizumab (Skyrizi) - An IL-23 antagonist for Crohn's disease. (Pubmed Central) - Dec 22, 2022
Key words:IOS, CAD/CAM, SCAN Bodies. No abstract available

||||||||||  Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
New P2/3 trial:  REMODEL-CD: Precise Infliximab Exposure and Pharmacodynamic Control (clinicaltrials.gov) -  Dec 21, 2022
P2/3, N=180, Not yet recruiting,  Sponsor: Children's Hospital Medical Center, Cincinnati

|||||||||| Eticovo (etanercept-ykro) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Observational data, Journal: Outcome of adult patients with JIA treated with the biosimilar Benepali: results of the biologic register JuMBO. (Pubmed Central) - Dec 16, 2022
Tolerability and effectiveness of the biosimilar Benepali were satisfactory and therapy survival was comparable to the originator. Further data on therapy with biologics and biosimilars such as Benepali must be collected by registries such as BiKeR and JuMBO in order to optimize therapy and patient outcomes and to reduce costs in the health system in the long term.



	Diseases Companies Products Productz Mechanisms of Action Sites